FDA Clearance Tracker · P130013-S025
Watchman Left Atrial Appendage Closure (LAAC) Device with Delivery System
Last checked: Nov 20, 2026Latest source record: Mar 1, 2019 (this decision)Source: openFDAMethods & limitations
Decided
Mar 1, 2019
Approved
Time to decision
84 days
Received Dec 7, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P130013-S025
- Device name
- Watchman Left Atrial Appendage Closure (LAAC) Device with Delivery System
- Applicant
- Boston Scientific Corp
- Applicant location
- Maple Grove, MN
- Received
- Dec 7, 2018
- Decided
- Mar 1, 2019
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P130013
Device type
- Device type
- System, appendage closure, left atrial (NGV)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for approval for a manufacturing site, Synergy Health Ireland Ltd., (a STERIS Company), located at IDA Business and Technology Park, Srah, Tullamore, County Offaly, Ireland, as a new ethylene oxide (EO) sterilization site for the WATCHMAN Left Atrial Appendage Closure (LAAC) Device with Delivery System.
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.